Your browser doesn't support javascript.
loading
Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents.
Assi, Hikmat H; Wong, Chihunt; Tipton, Kimberly A; Mei, Li; Wong, Ken; Razo, Jennifer; Chan, Chanty; Howng, Bruce; Sagert, Jason; Krimm, Michael; Diep, Linnea; Jang, Andrew; Nguyen, Margaret T; Lapuyade, Nicole; Singson, Victoria; Villanueva, Ruth; Paidhungat, Madan; Liu, Shouchun; Rangan, Vangipuram; Vasiljeva, Olga; West, James W; Richardson, Jennifer H; Irving, Bryan; Daniel, Dylan; Belvin, Marcia; Kavanaugh, W Michael.
Afiliação
  • Assi HH; CytomX Therapeutics, Inc., South San Francisco, California.
  • Wong C; CytomX Therapeutics, Inc., South San Francisco, California.
  • Tipton KA; CytomX Therapeutics, Inc., South San Francisco, California.
  • Mei L; CytomX Therapeutics, Inc., South San Francisco, California.
  • Wong K; CytomX Therapeutics, Inc., South San Francisco, California.
  • Razo J; CytomX Therapeutics, Inc., South San Francisco, California.
  • Chan C; CytomX Therapeutics, Inc., South San Francisco, California.
  • Howng B; CytomX Therapeutics, Inc., South San Francisco, California.
  • Sagert J; CytomX Therapeutics, Inc., South San Francisco, California.
  • Krimm M; CytomX Therapeutics, Inc., South San Francisco, California.
  • Diep L; CytomX Therapeutics, Inc., South San Francisco, California.
  • Jang A; CytomX Therapeutics, Inc., South San Francisco, California.
  • Nguyen MT; CytomX Therapeutics, Inc., South San Francisco, California.
  • Lapuyade N; CytomX Therapeutics, Inc., South San Francisco, California.
  • Singson V; CytomX Therapeutics, Inc., South San Francisco, California.
  • Villanueva R; CytomX Therapeutics, Inc., South San Francisco, California.
  • Paidhungat M; CytomX Therapeutics, Inc., South San Francisco, California.
  • Liu S; CytomX Therapeutics, Inc., South San Francisco, California.
  • Rangan V; CytomX Therapeutics, Inc., South San Francisco, California.
  • Vasiljeva O; CytomX Therapeutics, Inc., South San Francisco, California.
  • West JW; CytomX Therapeutics, Inc., South San Francisco, California.
  • Richardson JH; CytomX Therapeutics, Inc., South San Francisco, California.
  • Irving B; CytomX Therapeutics, Inc., South San Francisco, California.
  • Daniel D; CytomX Therapeutics, Inc., South San Francisco, California.
  • Belvin M; CytomX Therapeutics, Inc., South San Francisco, California.
  • Kavanaugh WM; CytomX Therapeutics, Inc., South San Francisco, California. mkavanaugh@cytomx.com.
Cancer Immunol Res ; 9(12): 1451-1464, 2021 12.
Article em En | MEDLINE | ID: mdl-34635485
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antígeno B7-H1 / Imunoterapia / Anticorpos Monoclonais Limite: Animals / Humans Idioma: En Revista: Cancer Immunol Res Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antígeno B7-H1 / Imunoterapia / Anticorpos Monoclonais Limite: Animals / Humans Idioma: En Revista: Cancer Immunol Res Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos